MPT
Medical Properties Trust, Inc.
There isn't enough reported data to score MPT yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
MPT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
MPT's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MPT.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
MPT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.2x | $1.71 | — |
| Cheap | 7.1x | $2.90 | +70% |
| Fair | 22x | $8.96 | +424% |
| Expensive | 26x | $10.48 | +513% |
Historical ranges are pointers, not guarantees.
MPT has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
MPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect MPT's earnings and profitability to decline, with its revenue holding steady.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over MPT on the outlook, with more favorable earnings and revenue expectations.
MPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.41 | +$1.58 |
| Q2 2026 | -$0.06 | +$2.32 |
| Q1 2026 | -$0.21 | +$2.55 |
| Q4 2025 | -$0.46 | +$3.56 |
| Q3 2025 | -$1.17 | +$3.28 |
| Q2 2025 | -$2.38 | +$0.54 |
| Q1 2025 | -$2.76 | -$0.31 |
| Q4 2024 | -$4.02 | -$3.08 |
MPT has returned to profit: it earned $0.41 per share over the past year, after losing money the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over MPT on earnings, with more consistent year-over-year improvement.
MPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $250.1M | +5.3% |
| Q2 2026 | $259.3M | +7.9% |
| Q1 2026 | $252.1M | +13% |
| Q4 2025 | $270.3M | +17% |
| Q3 2025 | $237.5M | +5.2% |
| Q2 2025 | $240.4M | -9.8% |
| Q1 2025 | $223.8M | -18% |
| Q3 2024 | $225.8M | -26% |
MPT's revenue is recovering but still below its 2022 peak: $250M last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.5% | -1.9 points |
| Q2 2026 | 3.3% | +0.5 points |
| Q1 2026 | 2.7% | +5.2 points |
| Q4 2025 | 14% | +1.8 points |
| Q3 2025 | -3.6% | +53 points |
| Q2 2025 | 2.9% | -4.6 points |
| Q1 2025 | -2.5% | -21 points |
| Q4 2024 | 12% | N/A |
MPT's operating margin was −5.5% last quarter, down 1.9 points from the same quarter a year ago, near the bottom of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over MPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over MPT on profitability, with a higher operating margin.
MPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $41.1M | +122% |
| Q2 2026 | $62.4M | +21% |
| Q1 2026 | -$14.3M | -3813% |
| Q4 2025 | $160.1M | +109% |
| Q3 2025 | $18.6M | -69% |
| Q2 2025 | $51.7M | +47% |
| Q1 2025 | $384K | -99% |
| Q4 2024 | $76.7M | -43% |
MPT has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
MPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -799K shares |
| 1 year | -0.7% | -4M shares |
| 3 years | -0.2% | -1.4M shares |
| 5 years | 0% | -158K shares |
| Available history | +21% | +102M shares |
MPT has 597M diluted shares, down 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2023 | $2M |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over MPT on shareholder dilution, with a more favorable share count trend.
MPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 27.0x | High |
| Q2 2026 | 28.8x | High |
| Q1 2026 | 29.0x | High |
| Q4 2025 | 30.7x | High |
| Q3 2025 | 32.3x | High |
| Q2 2025 | 30.0x | High |
| Q1 2025 | 24.9x | High |
| Q4 2024 | 20.3x | High |
MPT's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MPT.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS has the edge over MPT on leverage, with a lower net debt burden relative to earnings.
MPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 14.7 | Oversold |
| Stochastic | 2.8 | Oversold |
MPT's weekly RSI is 15 (oversold) and its Stochastic is 3 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
MPT PE vs Financial Services Sector
| Metric | MPT | Sector median | Relative |
|---|---|---|---|
| PE | 4.2x | 13x | 68% below |
| PE % | 0 | 63 | 63 pts below |
MPT has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
MPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 36% below |
| 20 week MA | $3.65 | 53% below |
| 50 week MA | $4.51 | 62% below |
| 100 week MA | $4.68 | 63% below |
| 200 week MA | $5.44 | 69% below |
MPT is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over MPT on trend strength, trading above more of its moving averages.
MPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.7 | $21.7 | +4.9% |
| 2021 | $21.7 | $22.7 | +4.3% |
| 2022 | $22.7 | $11.2 | -51% |
| 2023 | $11.2 | $4.91 | -56% |
| 2024 | $4.91 | $3.73 | -24% |
| 2025 | $3.73 | $5.08 | +36% |
| 2026 YTD | $5.08 | $1.71 | -66% |
MPT has finished lower in three of the last six years. It's down 66% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over MPT on returns for 2026, with the stronger performance.